Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

J&J Gains as FDA Says Its Covid Booster Shot Helps Immunity

Published 13/10/2021, 16:32
Updated 13/10/2021, 16:32
© Reuters.

© Reuters.

By Dhirendra Tripathi

Investing.com – Johnson & Johnson stock (NYSE:JNJ) rose by 0.5% in Wednesday’s trading as the Food and Drug Administration said the company’s booster shot against Covid-19 helped boost immune response.

The regulators cautioned that data was limited and they relied on the company’s own analysis for some of the findings, rather than conducting their own study.

The regulator’s view comes in response to the company’s request for authorization of its booster dose.

So far, the Pfizer (NYSE:PFE)-BioNTech (NASDAQ:BNTX) booster is the only to have been approved for administering to those above 60 and other high-risk people.

Along with J&J’s request, the FDA has before it a request from Moderna (NASDAQ:MRNA) for its booster dose.

The J&J shot is the only one in the U.S. carrying a single-dose application. All others are two-dose vaccines.

J&J recommends that a booster be given six months after the initial shot, though it could be given as early as two months also after the first.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.